Baseline characteristics of the study cohort
| . | All patients, n (%) . | sMut, n (%) . | No sMut, n (%) . | P value . |
|---|---|---|---|---|
| Number of patients | 233 (100) | 43 (18.5) | 190 (81.5) | |
| Gender | ||||
| Male | 111 (47.6) | 27 (62.8) | 84 (44.2) | .029 |
| Female | 122 (52.4) | 16 (37.2) | 106 (55.8) | |
| Age | ||||
| <60 y | 97 (41.6) | 6 (14.0) | 91 (47.9) | <.001 |
| ≥60 y | 136 (58.4) | 37 (86.0) | 99 (52.1) | |
| Median at diagnosis, n (range) | 63 (22-86) | 68 (34-86) | 62 (22-80) | |
| Type of AML | ||||
| De novo | 189 (81.1) | 35 (81.4) | 154 (81.1) | 1.000 |
| Secondary | 31 (13.3) | 5 (11.6) | 26 (13.7) | 1.000 |
| Therapy-related | 11 (4.7) | 3 (7.0) | 8 (42.0) | .431 |
| Unknown | 2 (0.9) | 0 | 2 (1.1) | |
| ELN 2017 Risk | ||||
| Favorable | 137 (58.8) | 30 (69.8) | 107 (56.3) | .124 |
| Intermediate | 68 (29.2) | 5 (11.6) | 63 (33.2) | .005 |
| Adverse | 22 (9.4) | 7 (16.3) | 15 (7.9) | .143 |
| Unknown | 6 (2.6) | 1 (2.3) | 5 (2.6) | |
| ELN 2022 Risk | ||||
| Favorable | 119 (51.1) | 26 (60.5) | 93 (48.9) | .182 |
| Intermediate | 88 (37.8) | 9 (20.9) | 79 (41.6) | .014 |
| Adverse | 22 (9.4) | 7 (16.3) | 15 (7.9) | .143 |
| Unknown | 4 (1.7) | 1 (2.3) | 3 (1.6) | |
| Cytogenetics | ||||
| Favorable | 1 (0.4) | 0 | 1 (0.5) | 1.000 |
| Intermediate | 207 (88.8) | 35 (81.4) | 172 (90.5) | .106 |
| Adverse | 8 (3.4) | 2 (4.7) | 6 (3.2) | .643 |
| Unknown | 17 (7.3) | 6 (14.0) | 11 (5.8) | |
| Most common mutations | ||||
| DNMT3A | 114 (48.9) | 15 (34.9) | 99 (52.1) | .044 |
| FLT3-ITD | 79 (33.9) | 11 (25.6) | 68 (35.8) | .218 |
| TET2 | 67 (28.7) | 17 (39.5) | 50 (26.3) | .095 |
| IDH1 | 37 (15.8) | 9 (20.9) | 28 (14.7) | .355 |
| FLT3-TKD | 35 (15.0) | 4 (9.3) | 31 (16.3) | .345 |
| NRAS | 29 (12.4) | 3 (6.9) | 26 (13.7) | .373 |
| IDH2 | 27 (11.6) | 6 (13.9) | 21 (11.1) | .600 |
| sMut | 43 (18.5) | 43 (100) | 0 | |
| Mutation burden, average | 3.4 | 4.1 | 3.3 | |
| Treatment | ||||
| Frontline | ||||
| Intensive | 177 (76.0) | 26 (60.5) | 151 (79.5) | .016 |
| Nonintensive | 50 (21.5) | 16 (37.2) | 34 (17.9) | .008 |
| No treatment | 6 (2.6) | 1 (2.3) | 5 (2.6) | 1.000 |
| Lines of therapy, average | 2 | 2 | 2 | |
| Allo-HCT | 109 (46.8) | 15 (34.9) | 94 (49.5) | .093 |
| . | All patients, n (%) . | sMut, n (%) . | No sMut, n (%) . | P value . |
|---|---|---|---|---|
| Number of patients | 233 (100) | 43 (18.5) | 190 (81.5) | |
| Gender | ||||
| Male | 111 (47.6) | 27 (62.8) | 84 (44.2) | .029 |
| Female | 122 (52.4) | 16 (37.2) | 106 (55.8) | |
| Age | ||||
| <60 y | 97 (41.6) | 6 (14.0) | 91 (47.9) | <.001 |
| ≥60 y | 136 (58.4) | 37 (86.0) | 99 (52.1) | |
| Median at diagnosis, n (range) | 63 (22-86) | 68 (34-86) | 62 (22-80) | |
| Type of AML | ||||
| De novo | 189 (81.1) | 35 (81.4) | 154 (81.1) | 1.000 |
| Secondary | 31 (13.3) | 5 (11.6) | 26 (13.7) | 1.000 |
| Therapy-related | 11 (4.7) | 3 (7.0) | 8 (42.0) | .431 |
| Unknown | 2 (0.9) | 0 | 2 (1.1) | |
| ELN 2017 Risk | ||||
| Favorable | 137 (58.8) | 30 (69.8) | 107 (56.3) | .124 |
| Intermediate | 68 (29.2) | 5 (11.6) | 63 (33.2) | .005 |
| Adverse | 22 (9.4) | 7 (16.3) | 15 (7.9) | .143 |
| Unknown | 6 (2.6) | 1 (2.3) | 5 (2.6) | |
| ELN 2022 Risk | ||||
| Favorable | 119 (51.1) | 26 (60.5) | 93 (48.9) | .182 |
| Intermediate | 88 (37.8) | 9 (20.9) | 79 (41.6) | .014 |
| Adverse | 22 (9.4) | 7 (16.3) | 15 (7.9) | .143 |
| Unknown | 4 (1.7) | 1 (2.3) | 3 (1.6) | |
| Cytogenetics | ||||
| Favorable | 1 (0.4) | 0 | 1 (0.5) | 1.000 |
| Intermediate | 207 (88.8) | 35 (81.4) | 172 (90.5) | .106 |
| Adverse | 8 (3.4) | 2 (4.7) | 6 (3.2) | .643 |
| Unknown | 17 (7.3) | 6 (14.0) | 11 (5.8) | |
| Most common mutations | ||||
| DNMT3A | 114 (48.9) | 15 (34.9) | 99 (52.1) | .044 |
| FLT3-ITD | 79 (33.9) | 11 (25.6) | 68 (35.8) | .218 |
| TET2 | 67 (28.7) | 17 (39.5) | 50 (26.3) | .095 |
| IDH1 | 37 (15.8) | 9 (20.9) | 28 (14.7) | .355 |
| FLT3-TKD | 35 (15.0) | 4 (9.3) | 31 (16.3) | .345 |
| NRAS | 29 (12.4) | 3 (6.9) | 26 (13.7) | .373 |
| IDH2 | 27 (11.6) | 6 (13.9) | 21 (11.1) | .600 |
| sMut | 43 (18.5) | 43 (100) | 0 | |
| Mutation burden, average | 3.4 | 4.1 | 3.3 | |
| Treatment | ||||
| Frontline | ||||
| Intensive | 177 (76.0) | 26 (60.5) | 151 (79.5) | .016 |
| Nonintensive | 50 (21.5) | 16 (37.2) | 34 (17.9) | .008 |
| No treatment | 6 (2.6) | 1 (2.3) | 5 (2.6) | 1.000 |
| Lines of therapy, average | 2 | 2 | 2 | |
| Allo-HCT | 109 (46.8) | 15 (34.9) | 94 (49.5) | .093 |
sMut: ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2.